Disrupting circadian control of peripheral myogenic reactivity mitigates cardiac injury following myocardial infarction.

"Conflict of interest: J.T.K. and D.L. have consulted for Qanatpharma AG (Stans, Switzerland) and Aphaia Pharma AG (Zug, Switzerland) within the last 36 months. J.H. is an employee of Qanatpharma AG. S.S.B. is a founder and executive board member of Qanatpharma AG and Aphaia Pharma AG. Aphaia Pharma AG had no financial or intellectual involvement in this article. Qanatpharma AG played no role in study design, data collection/analysis, decision to publish, or the preparation of the publication. Aside from J.T.K., D.L., J.H., and SSB, none of the other authors have relationships to industry."

"Funding This work was supported by: a Heart and Stroke Foundation research grant (StSB, G-17-0017612), Career Investigator Award (StSB CI-7432) and Mid-Career Investigator Awards (StSB and TAM); the Canadian Institutes of Health Research (CIHR; projects 450152 and 450171 to TAM); a post-doctoral fellowship from a CIHR-funded Sleep and Biological Rhythms Team Grant (JTK); a Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research post-doctoral fellowship (JTK); infrastructure grants from the Canadian Foundation for Innovation and Ontario Research Fund (StSB, 11810); and seed funding from Qanatpharma AG (Stans, Switzerland). The funders had no role in study design, data collection and analysis, decision to publish or the preparation of the publication."